Sushmita Sudarshan

For decades, meaningful progress in biotechnology depended on access to million to billion-dollar facilities, specialized infrastructure, and industrial-scale equipment. Today, that paradigm is rapidly shifting. A new generation of tools, from smart shake flasks and modular bioreactors to microfluidic platforms, desktop DNA printers, and compact sequencing devices; is compressing the scale of biological experimentation while expanding who can participate. These technologies are transforming the economics of innovation, enabling startups, academic labs, and distributed research teams to design, build, and test biological systems without massive capital investment. As instrumentation becomes smaller, smarter, and increasingly automated, biology is moving from centralized mega-facilities toward a more distributed model of experimentation. This session explores how advances in lab automation, miniaturized bioreactors, and accessible bioinstrumentation are lowering the barriers to experimentation — and what this shift means for the speed, diversity, and geography of the next wave of bioinnovation.